醛固酮合酶 (CYP11B2) 染色模式如何影响单侧原发性醛固酮增多症患者的预后尚不清楚。我们假设分类系统将有利于未来的研究，并且单侧肾上腺切除术后的临床和生化结果受到不同 CYP11B2 染色模式的影响。对 2015 年 1 月至 2023 年 9 月因原发性醛固酮增多症接受肾上腺切除术的患者进行了回顾性评价。分析了人口统计学、临床和病理数据。开发了染色模式分类系统。将临床和生化结果与染色模式进行比较，以评估差异并确定相关性。使用 SPSS 进行描述性和统计分析。纳入了 43 名患者。确定了以下 CYP11B2 染色模式：（1）单个腺瘤； (2) 产生醛固酮的结节或微结节； (3)类型1和类型2的组合； (4)增生； (5)产生醛固酮的肾上腺皮质癌。总共，43 个中的 23 个仅在单个腺瘤中显示 CYP11B2 染色。 3/23 的染色涉及腺瘤的一部分。 4/9 年龄<40 岁的患者在非腺瘤组织中有 CYP11B2 染色区域。 43 例中有 37 例 (86%) 达到生化完全治愈，23.2% 达到临床完全治愈。染色模式与性别、种族或年龄之间没有差异。 CYP11B2 染色模式与早期临床或生化结果无关。原发性醛固酮增多症患者的肾上腺切除标本显示多种 CYP11B2 染色模式，包括许多患者的非腺瘤组织。这些模式对临床结果的影响需要进一步研究。染色模式的统一分类将有助于跨研究提供一致的报告。版权所有 © 2024 Elsevier Inc. 保留所有权利。

How aldosterone synthase (CYP11B2) staining patterns impact patient outcomes in those with unilateral primary aldosteronism is not well described. We hypothesized that a system of categorization would benefit future research and that clinical and biochemical outcomes after unilateral adrenalectomy are impacted by different CYP11B2 staining patterns.A retrospective review of patients undergoing adrenalectomy for primary aldosteronism from January 2015 to September 2023 was conducted. Demographics, clinical, and pathologic data were analyzed. A system of categorization of staining patterns was developed. Clinical and biochemical outcomes were compared with staining patterns to assess differences and determine correlation. Descriptive and statistical analyses were performed using SPSS.Forty-three patients were included. The following CYP11B2 staining patterns were identified: (1) single adenoma; (2) aldosterone producing nodule(s) or micronodule(s); (3) combination of type 1 and type 2; (4) hyperplasia; and (5) aldosterone-producing adrenocortical cancer. In total, 23 of 43 revealed CYP11B2 staining in a single adenoma only. Staining in 3/23 involved a portion of the adenoma. 4/9 patients age <40 had areas of CYP11B2 staining in nonadenomatous tissue. Complete biochemical cure was noted in 37 of 43 (86%) and complete clinical cure in 23.2%. There were no differences between staining pattern and sex, race, or age. CYP11B2 staining pattern did not correlate with early clinical or biochemical outcomes.Adrenalectomy specimens from patients treated for primary aldosteronism reveal multiple CYP11B2 staining patterns, including in nonadenomatous tissue in many patients. The impact of these patterns on clinical outcomes requires additional investigation. Uniform categorization of staining patterns will allow for consistent reporting across studies.Copyright © 2024 Elsevier Inc. All rights reserved.